Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

COMy 2022 | Managing lenalidomide-refractory myeloma patients

In this video, Karthik Ramasamy, MBBS, MRCP, FRCPath, PhD, Oxford University Hospitals NHS Foundation Trust, Oxford, UK, discusses treatment approaches for lenalidomide-refractory myeloma patients. Dr Ramasamy highlights the combination of a monoclonal antibody plus a proteasome inhibitor and dexamethasone, which is currently used in the UK. Following this, Dr Ramasamy mentions novel combinations going through NICE approval and the importance of clinical trials in providing more options for lenalidomide-refractory patients. This interview took place at the 8th World Congress on Controversies in Multiple Myeloma (COMy) 2022, held in Paris, France.